Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927019 | 0.93 | GAA (0.54) | GAATDP1PKMPOLBRAB9A | |
| SCHEMBL14052805 | 0.88 | GAA (0.55) | GAATDP1PKMPOLBALDH1A1 | |
| SCHEMBL31319578 | 0.82 | TDP1 (0.44) | GAATDP1PKMPOLBKMT2A | |
| SCHEMBL12725198 | 0.82 | TDP1 (0.44) | GAATDP1PKMPOLBKMT2A | |
| SCHEMBL1875515 | 0.81 | SMN1; SMN2 (0.45) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL29544423 | 0.81 | TDP1 (0.44) | GAATDP1PKMPOLBKMT2A | |
| SCHEMBL12800195 | 0.81 | TDP1 (0.46) | GAATDP1PKMPOLBKMT2A | |
| SCHEMBL12725321 | 0.80 | TDP1 (0.43) | GAATDP1PKMPOLBKMT2A | |
| Methamphetamine SCHEMBL28242498 | 0.79 | GAA (0.45) | GAATDP1PKMPOLBRAB9A | |
| SCHEMBL570007 | 0.79 | SMN1; SMN2 (0.57) | GAATDP1PKMPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059503-B1 | AMINOPYRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC DISEASES CONTAINING THE SAME | KOREA RES INST CHEM TECH (KR) | 2015-08-26 | — | — | EP | disclosed |
| US-7939550-B2 | Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-05-10 | — | — | US | disclosed |
| US-20100063106-A1 | AMINOPYRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC DISEASES CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-11 | — | — | US | disclosed |
| EP-2059503-A1 | AMINOPYRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC DISEASES CONTAINING THE SAME | Korea Research Institute Of Chemical Technology (KR) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008051047-A1 | AMINOPYRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC DISEASES CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063106-A1 | AMINOPYRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC DISEASES CONTAINING THE SAME | CASP3, ABAT, AIFM1 | GAA 1793/4885TDP1 2801/4885PKM 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.